Cross-institution positioning
Aug 6, 2026Mixed positioning. No institution has two comparable Schedule 13 observations yet.
Source: Schedule 13 researchMedline Inc.
Latest stored close $36.26 as of Oct 9, 2026 View live quote ↗
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
Mixed positioning. No institution has two comparable Schedule 13 observations yet.
Source: Schedule 13 research2 increased/new, 0 reduced/exited across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsOver the last 90 days, SEC-coded non-derivative P/S activity includes 0 purchases by 0 reporting owners and 11 sales by 3 reporting owners. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/52 non-amendment material events in the last 90 days; Latest classified evidence: Results of operations / financial condition. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataRevenue +11.6% YoY; Net income -57.8% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsRecent close is 3% through its reported 52-week range.
Source: Stored historical price seriesFiled Aug 6, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
See each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Comparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Compare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd. | SOpen-market or private sale | Class A Common Stock | 7.2M | $35.05 | Indirect | Oct 6, 2026 |
| Oct 6, 2026 | GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd. | SOpen-market or private sale | Class A Common Stock | 2.1M | $35.05 | Direct | Oct 6, 2026 |
| Oct 5, 2026 | GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd. | SOpen-market or private sale | Class A Common Stock | 1.7M | $35.78 | Direct | Oct 6, 2026 |
| Oct 2, 2026 | GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd. | SOpen-market or private sale | Class A Common Stock | 7.1M | $34.33 | Indirect | Oct 6, 2026 |
| Oct 2, 2026 | GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd. | SOpen-market or private sale | Class A Common Stock | 2.6M | $35.35 | Direct | Oct 6, 2026 |
| Aug 19, 2026 | Boyle James M | AGrant, award, or other acquisition · derivative | Incentive Units of Medline Holdings, LP | 764.3K | — | Indirect | Aug 21, 2026 |
| Aug 19, 2026 | Miller Stephen L | AGrant, award, or other acquisition · derivative | Incentive Units of Medline Holdings, LP | 87.7K | — | Indirect | Aug 21, 2026 |
| Aug 14, 2026 | GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd. | SOpen-market or private sale | Class A Common Stock | 100.0K | $35.80 | Direct | Aug 17, 2026 |
| Aug 13, 2026 | GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd. | SOpen-market or private sale | Class A Common Stock | 1.5M | $35.80 | Direct | Aug 17, 2026 |
| Aug 7, 2026 | GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd. | SOpen-market or private sale | Class A Common Stock | 590.3K | $35.58 | Direct | Aug 11, 2026 |
| Aug 6, 2026 | Mozart Holdco, Inc. | CConversion of derivative · derivative | Common Units of Medline Holdings, LP | 500.0K | $0.00 | Direct | Aug 7, 2026 |
| Aug 6, 2026 | Mozart Holdco, Inc. | JOther transaction | Class B Common Stock | 500.0K | $0.00 | Direct | Aug 7, 2026 |
| Aug 6, 2026 | Mozart Holdco, Inc. | CConversion of derivative | Class A Common Stock | 500.0K | $0.00 | Direct | Aug 7, 2026 |
| Aug 6, 2026 | GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd. | SOpen-market or private sale | Class A Common Stock | 272.0K | $35.33 | Direct | Aug 7, 2026 |
| Aug 5, 2026 | GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd. | SOpen-market or private sale | Class A Common Stock | 265.7K | $36.48 | Direct | Aug 7, 2026 |
| Aug 5, 2026 | GIC Private Ltd, GIC Special Investments Pte Ltd, Hux Investment Pte. Ltd. | SOpen-market or private sale | Class A Common Stock | 1.7M | $35.46 | Direct | Aug 7, 2026 |
| Jun 16, 2026 | Golwas Douglas P | MExercise or conversion of derivative · derivative | Common Units of Medline Holdings, LP | 100.0K | $0.00 | Indirect | Jun 17, 2026 |
| Jun 16, 2026 | Golwas Douglas P | DDisposition to issuer | Class B Common Stock | 100.0K | — | Direct | Jun 17, 2026 |
| Jun 16, 2026 | Golwas Douglas P | SOpen-market or private sale | Class A Common Stock | 38.0K | $37.05 | Direct | Jun 17, 2026 |
| Jun 16, 2026 | Golwas Douglas P | SOpen-market or private sale | Class A Common Stock | 62.0K | $36.60 | Direct | Jun 17, 2026 |
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Aug 5, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Jul 9, 2026 | 8-K | 5.02 | Director or executive change | — | Filing |
| Jun 12, 2026 | 8-K | 5.07 | Shareholder vote results | — | Filing |
| Jun 2, 2026 | 8-K | 1.01, 2.03, 8.01, 9.01 | Material definitive agreement; New direct financial obligation; Other event; Financial statements / exhibits | Debt | Filing |
| May 26, 2026 | 424B4 | — | Prospectus filing | Capital-related | Filing |
| May 20, 2026 | S-1 | — | Securities registration statement | Capital-related | Filing |
| May 6, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Mar 6, 2026 | 424B4 | — | Prospectus filing | Capital-related | Filing |
| Mar 3, 2026 | S-1 | — | Securities registration statement | Capital-related | Filing |
| Feb 25, 2026 | S-8 | — | Employee-plan securities registration | Equity | Filing |
| Feb 25, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Dec 22, 2025 | 8-K | 1.01, 3.03, 5.02, 5.03, 8.01, 9.01 | Material definitive agreement; Material modification of security-holder rights; Director or executive change; Charter or bylaw change; Other event; Financial statements / exhibits | Equity | Filing |
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
| Period | Revenue | YoY |
|---|---|---|
| Ended Jun 27, 2026 | $7.7B | +11.6% |
| Ended Mar 28, 2026 | $7.4B | +10.7% |
| Ended Jun 28, 2025 | $6.9B | — |
| Ended Mar 29, 2025 | $6.6B | — |
| Period | Revenue | YoY |
|---|---|---|
| Ended Dec 31, 2025 | $28.4B | +11.5% |
| Ended Dec 31, 2024 | $25.5B | +9.8% |
| Ended Dec 31, 2023 | $23.2B | — |
Dated price context from the historical market series already collected for this security.
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Fidelity / FMR CIK0000315066 | Jun 30, 2026 observed Aug 6, 2026 filed · 37d Initial Schedule 13G | Initial Schedule 13G | 46.9K | 5.50% | $39.44 | $34.51 | $36.26 |
| Fidelity / FMR CIK0000315066 | Dec 31, 2025 quarter end Feb 17, 2026 filed Form 13F quarter-end evidence | Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal. | 26.4M | $36.26 |
Compare MDLN with other securities showing similar institutional activity or recent accumulation across several tracked institutions.